Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Immune checkpoint inhibitors (ICIs) are revolutionary cancer treatments, inspired by Nobel Prize-winning research on cancer's immune evasion mechanisms.
• ICIs have led to durable remissions, even cures, in some patients with advanced metastatic cancer.
• Despite successes, significant challenges remain, including immune-related toxicities and widespread tumor resistance.

Purpose of the Study:

• To provide a comprehensive overview of immune checkpoint inhibitors (ICIs) in cancer therapy.
• To discuss the benefits, adverse effects, and resistance mechanisms associated with ICIs.
• To explore complex clinical progression patterns and current biomarker limitations for ICI response.

Main Methods:

• Literature review and synthesis of current research on immune checkpoint inhibitors (ICIs).
• Analysis of clinical outcomes, including efficacy, toxicity, and progression patterns.
• Evaluation of existing biomarkers for predicting ICI response and resistance.

Main Results:

• ICIs have transformed treatment for many cancers, offering potential cures.
• Significant immune-related toxicities and tumor resistance limit ICI effectiveness.
• Unusual progression patterns like pseudo-progression and hyper-progression complicate treatment assessment.
• Current biomarkers (microsatellite instability, tumor mutational burden, PD-L1) are imperfect predictors of response.

Conclusions:

• ICIs represent a major advance in cancer immunotherapy, offering hope for durable responses.
• Addressing toxicity and overcoming resistance are critical for improving ICI therapy.
• Further research into the complex tumor-immune interactions is needed to refine patient selection and treatment strategies.